PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
 
Biologics. 2012; 6: 299–306.
Published online Aug 28, 2012. doi:  10.2147/BTT.S30180
PMCID: PMC3437740
OnabotulinumtoxinA in the treatment of neurogenic bladder
Aziz Gulamhusein and Altaf Mangera
Department of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom
Correspondence: Altaf Mangera, Department of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom, Tel +447 8113 3773, Email mangeraaltaf/at/hotmail.com
Abstract
This review examines the evidence for use of onabotulinumtoxinA in the treatment of neurogenic lower urinary tract dysfunction. Since its first use in 1988 to treat detrusor sphincter dyssynergia, use of botulinum toxin has increased in this group of patients. We discuss the mechanism of action, patient selection, dosing, efficacy, and side effect profile of this now licensed treatment option.
Keywords: neurogenic bladder, botulinum toxin, onabotulinumtoxinA, neurogenic detrusor overactivity, detrusor sphincter dyssynergia
Articles from Biologics : Targets & Therapy are provided here courtesy of
Dove Press